Morag Griffin, MBChB, BMSc(hons), MRCP UK, FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses interim results from the ALXN1210-PNH-401 study (NCT04320602) assessing the safety of switching from high-dose eculizumab to weight-based dosing of ravulizumab to treat patients with paroxysmal nocturnal hemoglobinuria (PNH). Dr Griffin explains the justification for this study, identifies the primary endpoints, and shares promising data collected thus far. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Негізгі бет Switching from high-dose eculizumab to weight-based ravulizumab in patients with PNH
Пікірлер